Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 5/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.38 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.38 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20142278 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBGGPS1CA12 | |
| SCHEMBL20142325 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBGGPS1CA12 | |
| SCHEMBL20142242 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBGGPS1CA12 | |
| SCHEMBL20142376 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBGGPS1CA12 | |
| SCHEMBL20142505 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBGGPS1CA12 | |
| SCHEMBL10464715 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBGGPS1CA12 | |
| SCHEMBL19992803 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBGGPS1CA12 | |
| SCHEMBL20142869 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBGGPS1CA12 | |
| SCHEMBL21126454 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBGGPS1CA12 | |
| SCHEMBL15006368 | 1.00 | DNM1 (0.55) | DNM1TSHRTHRBGGPS1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6413929-B1 | MIXTURE OF PEROXY COMPOUND AND AMINE | BASF AKTIENGESELLSCHAFT (DE) | 2002-07-02 | — | — | US | claimed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11707457-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | SYNDEVRX, INC. | 2023-07-20 | — | — | US | disclosed |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230165892-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230048989-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2023-02-16 | — | — | US | disclosed |
| US-9757373-B2 | MetAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-9750737-B2 | METAP2 inhibitors and methods of treating obesity | SYNDEVRX, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9730955-B2 | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof | SYNDEVRX, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-20170196830-A1 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUNCTION | SYNDEVRX, INC. | 2017-07-13 | — | — | US | disclosed |
| US-9585909-B2 | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof | SYNDEVRX, INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-20170028014-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. | 2017-02-02 | — | — | US | disclosed |
| WO-2014037340-A1 | USE OF SUBSTITUTED 2-AMIDOBENZIMIDAZOLES, 2-AMIDOBENZOXAZOLES AND 2-AMIDOBENZOTHIAZOLES OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-03-13 | — | — | WO | disclosed |
| EP-0892846-B1 | BLEACHING POWER ENHANCERS FOR BLEACHES AND TEXTILE WASHING COMPOSITIONS | BASF AG (DE) | 2002-10-23 | — | — | EP | disclosed |
| US-6413929-B1 | MIXTURE OF PEROXY COMPOUND AND AMINE | BASF AKTIENGESELLSCHAFT (DE) | 2002-07-02 | — | — | US | disclosed |
| US-6130198-A | Bleaching efficiency boosters for bleach and textile detergent compositions | BASF AKTIENGESELLSCHAFT (DE) | 2000-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132715-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DNM1 4044/4885TSHR 3319/4885THRB 1824/4885 |
| US-20170028014-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | DNM1 1835/4885TSHR 3406/4885THRB 1991/4885 |
| US-20230225996-A1 | BIOMARKERS OF METAP2 INHIBITORS AND APPLICATIONS THEREOF | METAP2, METAP1, PEBP1 | DNM1 2126/4885TSHR 4170/4885THRB 3137/4885 |
| US-20230165892-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | DNM1 750/4885TSHR 4565/4885THRB 4582/4885 |
| US-20230048989-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | METAP2, ADIPOR2, METAP1 | DNM1 1835/4885TSHR 3406/4885THRB 1991/4885 |
| US-20230219945-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DNM1 4044/4885TSHR 3319/4885THRB 1824/4885 |
| US-20230190940-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DNM1 4044/4885TSHR 3319/4885THRB 1824/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | DNM1 4044/4885TSHR 3319/4885THRB 1824/4885 |
| US-20170196830-A1 | TREATMENT FOR TUMORS DRIVEN BY METABOLIC DYSFUNCTION | PCK2, GOT2, PC | DNM1 816/4885TSHR 3136/4885THRB 2074/4885 |
| US-20230110180-A1 | CDK2 DEGRADERS AND USES THEREOF | CDK2, CDK20, CDK1 | DNM1 4066/4885TSHR 3442/4885THRB 3030/4885 |
| US-11707457-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | DNM1 4044/4885TSHR 3319/4885THRB 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.